<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1134-8046</journal-id>
<journal-title><![CDATA[Revista de la Sociedad Española del Dolor]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Soc. Esp. Dolor]]></abbrev-journal-title>
<issn>1134-8046</issn>
<publisher>
<publisher-name><![CDATA[Inspira Network Group, S.L ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1134-80462018000200094</article-id>
<article-id pub-id-type="doi">10.20986/resed.2017.3592/2017</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Venlafaxina en el tratamiento del dolor neuropático]]></article-title>
<article-title xml:lang="en"><![CDATA[Venlafaxine in the treatment of neuropathic pain]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alcántara-Montero]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Don Benito-Villanueva de la Serena Unidad del Dolor ]]></institution>
<addr-line><![CDATA[Badajoz ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<volume>25</volume>
<numero>2</numero>
<fpage>94</fpage>
<lpage>105</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1134-80462018000200094&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1134-80462018000200094&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1134-80462018000200094&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La venlafaxina fue el primer antidepresivo inhibidor de la recaptación de serotonina y noradrenalina autorizado en España. Aunque no tiene indicación en ficha técnica en el tratamiento del dolor neuropático, hay guías de práctica clínica en las que la venlafaxina aparece en primera o segunda línea de tratamiento.  Desarrollo:  Tras una búsqueda bibliográfica, en este artículo se resumen los datos farmacológicos más relevantes de la venlafaxina, así como la bibliografía específica de este fármaco en dolor neuropático.  Conclusiones:  La venlafaxina es un fármaco seguro y bien tolerado para el tratamiento sintomático del dolor neuropático. Aunque la evidencia actual es bastante alentadora (en dosis de al menos 150 mg/día), son necesarias nuevas investigaciones para ampliar estos hallazgos, particularmente cuando se compara con otros posibles agentes farmacológicos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Venlafaxine was the first the first serotonin norepinephrine reuptake inhibitor antidepressant to authorized in Spain. Although there is no indication in the data sheet in the treatment of neuropathic pain, there are clinical practice guidelines in which venlafaxine appears in the first or second line of treatment.  Development:  Following a literature search, this article summarizes the most relevant pharmacological data of venlafaxine, as well as the specific literature of this drug in neuropathic pain.  Conclusions:  Venlafaxine is a safe and well tolerated drug for the symptomatic treatment of neuropathic pain. Although the current evidence is quite encouraging (at doses of at least 150 mg/day), further research is needed to extend these findings, particularly when is compared to other possible pharmacological agents.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Antidepressants]]></kwd>
<kwd lng="en"><![CDATA[neuropathic pain]]></kwd>
<kwd lng="en"><![CDATA[serotonin norepinephrine reuptake inhibitor]]></kwd>
<kwd lng="en"><![CDATA[neuropathy]]></kwd>
<kwd lng="en"><![CDATA[diabetic polyneuropathy]]></kwd>
<kwd lng="en"><![CDATA[venlafaxine]]></kwd>
<kwd lng="es"><![CDATA[Antidepresivos]]></kwd>
<kwd lng="es"><![CDATA[dolor neuropático]]></kwd>
<kwd lng="es"><![CDATA[inhibidor recaptación serotonina noradrenalina]]></kwd>
<kwd lng="es"><![CDATA[neuropatía]]></kwd>
<kwd lng="es"><![CDATA[polineuropatía diabética]]></kwd>
<kwd lng="es"><![CDATA[venlafaxina]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Neuropathic pain redefinition and a grading system for clinical and research purposes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Treede]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Cruccu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dostrovsky]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2008</year>
<volume>70</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1630-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of chronic pain with neuropathic characteristics in the general population]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bouhassira]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lantéri-Minet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Attal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Laurent]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Touboul]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain]]></source>
<year>2008</year>
<volume>136</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>380-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmader]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Pain]]></source>
<year>2002</year>
<volume>18</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>350-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The burden of neuropathic pain a systematic review and meta-analysis of health utilities]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doth]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain]]></source>
<year>2010</year>
<volume>149</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>338-44</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Major depressive disorder and sleep disturbance in patients with chronic pain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emery]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Kowal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain Res Manag]]></source>
<year>2014</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dworkin]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for the pharmacological management of neuropathic pain an overview andliterature update]]></article-title>
<collab>O'Connor AB.Audette J.Baron R.Gourlay GK.Haanpää ML</collab>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2010</year>
<volume>85</volume>
<numero>3 Suppl</numero>
<issue>3 Suppl</issue>
<page-range>S3-14</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence and characterization of neuropathic pain in a primary-care setting in Spain a cross-sectional, multicentre, observational study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Saldaña]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vilardaga]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rejas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Drug Investig]]></source>
<year>2009</year>
<volume>29</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>441-50</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Neuropathic pain diagnosis, pathophysiological mechanisms, and treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Binder]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wasner]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Neurol]]></source>
<year>2010</year>
<volume>9</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>807-19</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="">
<source><![CDATA[Venlafaxina MedP EU-FT]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Neuropathic pain in adults: pharmacological management in non-specialist settings]]></article-title>
<collab>NICE</collab>
<source><![CDATA[NICE Guidelines]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[NeuPSIG guidelines on neuropathic pain assessment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haanpää]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Attal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Backonja]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bouhassira]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain]]></source>
<year>2011</year>
<volume>152</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-27</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[EFNS guidelines on neuropathic pain assessment revised 2009]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruccu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sommer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Attal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[García-Larrea]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Neurol]]></source>
<year>2010</year>
<volume>17</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1010-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Recomendaciones para el tratamiento del dolor neuropático]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[González- Escalada]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Camba]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Portolés]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Soc Esp Dolor]]></source>
<year>2009</year>
<volume>16</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>445-67</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diagnóstico y tratamiento del dolor neuropático]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Salio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ribera]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Collado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Clin(Barc)]]></source>
<year>2009</year>
<volume>133</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>629-36</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacological management of chronic neuropathic pain revised consensus statement from the Canadian Pain Society]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moulin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Boulanger]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dao]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Finley]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain Res Manag]]></source>
<year>2014</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>328-35</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacotherapy for neuropathic pain in adults a systematic review and meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finnerup]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[Attal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Haroutounian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McNicol]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dworkin]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Neurol]]></source>
<year>2015</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>162-73</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evidence-based guideline Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bril]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[England]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Franklin]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Backonja]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[del Toro]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2011</year>
<volume>76</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1758-65</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montgomery]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<source><![CDATA[CNS Spectrums]]></source>
<year>2008</year>
<volume>13</volume>
<numero>7 Suppl 11</numero>
<issue>7 Suppl 11</issue>
<page-range>27-33</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of neuropathic pain with venlafaxine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sumpton]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Moulin]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2001</year>
<volume>35</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>557-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Venlafaxine A review of its pharmacology and therapeutic potential in depression]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holliday]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Benfield]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Drugs]]></source>
<year>1995</year>
<volume>49</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>280-94</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Venlafaxine for neuropathic pain in adults]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Buggy]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Henman]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2015</year>
<numero>8</numero>
<issue>8</issue>
<page-range>CD011091</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pain, pain, go away antidepressants and pain management]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sansone]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Sansone]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Psychiatry (Edgmont)]]></source>
<year>2008</year>
<volume>5</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>16-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Complex regional pain syndrome practical diagnostic and treatment guidelines, 4th edition]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harden]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Oaklander]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Burton]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Swan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain Med]]></source>
<year>2013</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>180-229</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Venlafaxine in neuropathic pain following treatment of breast cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tasmuth]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Härtel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kalso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Pain]]></source>
<year>2002</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-24</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Venlafaxine versus imipramine in painful polyneuropathy a randomized controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sindrup]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Bach]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Madsen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gram]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2003</year>
<volume>60</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1284-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Venlafaxine in the treatment of atypical facial pain a randomized controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forssell]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tasmuth]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tenovuo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Hampf]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kalso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[J Orofac Pain]]></source>
<year>2004</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>131-7</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Venlafaxine extended release in the treatment of painful diabetic neuropathy a double blind, placebo controlled study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowbotham]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Goli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kunz]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Lei]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain]]></source>
<year>2004</year>
<volume>110</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>697-706</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients a double blind, placebo controlled study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yucel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ozyalcin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Koknel Talu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kiziltan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Yucel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[OK]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Pain]]></source>
<year>2005</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>407-16</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy a randomized, double-blind and double-dummy, controlled multi-center trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[H-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Q-F]]></given-names>
</name>
<name>
<surname><![CDATA[Dian-Ping]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[An]]></surname>
<given-names><![CDATA[Z-M]]></given-names>
</name>
<name>
<surname><![CDATA[Yu-Ping]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ran]]></surname>
<given-names><![CDATA[X-W]]></given-names>
</name>
</person-group>
<source><![CDATA[Chinese Journal of Evidence-Based Medicine]]></source>
<year>2006</year>
<volume>6</volume>
<page-range>321-7</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kadiroglu]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Sit]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kayabasi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tuzcu]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Tasdemir]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yilmaz]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<source><![CDATA[J Diabetes Complications]]></source>
<year>2008</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>241-5</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evaluation of efficacy of the peri-operative administration of venlafaxine or gabapentin on acute and chronic post-mastectomy pain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amr]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Yousef]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Pain]]></source>
<year>2010</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>381-5</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Durand]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Deplanque]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Montheil]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gornet]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Scotte]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mir]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Oncol]]></source>
<year>2012</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>200-5</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy A randomized, double-blind trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Razazian]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Baziyar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moradian]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Afshari]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bostani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmoodi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurosciences (Riyadh)]]></source>
<year>2014</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>192-8</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression a randomized, controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Bombardier]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Chiodo]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tate]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Phys Med Rehabil]]></source>
<year>2015</year>
<volume>96</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>680-9</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eardley]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Toth]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pain Res]]></source>
<year>2010</year>
<volume>3</volume>
<page-range>33-49</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity a single-center retrospective case-control study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kus]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Aktas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Alpak]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kalender]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Sevinc]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kul]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Support Care Cancer]]></source>
<year>2016</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2085-91</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiology of refractory neuropathic pain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain Pract]]></source>
<year>2006</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-6</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antidepressants for neuropathic pain a Cochrane review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saarto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wiffen]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2010</year>
<volume>81</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1372-3</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evidence of the dual mechanisms of action of venlafaxine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Rudolph]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Preskorn]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Gen Psychiatry]]></source>
<year>2000</year>
<volume>57</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>503-9</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkinson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Seminars in General Adult Psychiatry]]></source>
<year>2007</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[RCP Psychiatry Publications]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Serotonin norepinephrine reuptake inhibitors A pharmacological comparison]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sansone]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Sansone]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Innov Clin Neurosci]]></source>
<year>2014</year>
<volume>11</volume>
<numero>3-4</numero>
<issue>3-4</issue>
<page-range>37-42</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guidance on the management of pain in older people]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdulla]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Gaffin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Age Ageing]]></source>
<year>2013</year>
<volume>42</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>i1-57</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
